The biology of p38 kinase: A central role in inflammation

Current Topics in Medicinal Chemistry

Volumn 5, Issue 10, 2005, Pages 921-928

  Schieven, Gary L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ADALIMUMAB; C REACTIVE PROTEIN; CHEMOKINE; CHEMOKINE RECEPTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DORAMAPIMOD; ETANERCEPT; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INFLIXIMAB; INTERLEUKIN 1BETA; ISOENZYME; L 790070; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SCIO 469; SD 282; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 702;

ALLODYNIA; CLINICAL TRIAL; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME POLYMORPHISM; HUMAN; HYPERALGESIA; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

ARTHRITIS, RHEUMATOID; CHEMOKINES; CYTOKINES; ENDOTHELIUM; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; OSTEOCLASTS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744496768     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054985902     Document Type: Review

References (64)

1. Kumar, S.; Boehm, J.; Lee, J. C. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Disc. 2003, 2, 717-726.
2. Saklatvala, J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr. Opin. Pharmacol. 2004, 4, 372-7.
3. Hale, K. K.; Trollinger, D.; Rihanek, M.; Manthey, C. L. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J. Immunol. 1999, 162, 4246-52.
4. Mudgett, J. S.; Ding, J.; Guh-Siesel, L.; Chartrain, N. A.; Yang, L.; Gopal, S.; Shen, M. M. Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc. Natl. Acad. Sci. USA 2000, 97, 10454-9.
5. Kim, J. M.; White, J. M.; Shaw, A. S.; Sleckman, B. P. MAPK p38 {alpha} Is Dispensable for Lymphocyte Development and Proliferation. J. Immunol. 2005, 174, 1239-44.
6. Boppart, M. D.; Asp, S.; Wojtaszewski, J. F.; Fielding, R. A.; Mohr, T.; Goodyear, L. J. Marathon running transiently increases c-Jun NH2-terminal kinase and p38 activities in human skeletal muscle. J. Physiol. 2000, 526 Pt 3, 663-9.
7. Long, Y. C.; Widegren, U.; Zierath, J. R. Exercise-induced mitogen-activated protein kinase signalling in skeletal muscle. Proc. Nutr. Soc. 2004, 63, 227-32.
8. Akimoto, T.; Pohnert, S. C.; Li, P.; Zhang, M.; Gumbs, C.; Rosenberg, P. B.; Williams, R. S.; Yan, Z. Exercise Stimulates Pgc-1alpha Transcription in Skeletal Muscle through Activation of the p38 MAPK Pathway. J. Biol. Chem. 2005, 280, 19587-93.
9. Ge, B.; Gram, H.; Di Padova, F.; Huang, B.; New, L.; Ulevitch, R. J.; Luo, Y.; Han, J. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha, Science 2002, 295, 1291-4.
10. Ohkusu-Tsukada, K.; Tominaga, N.; Udono, H.; Yui, K. Regulation of the maintenance of peripheral T-cell anergy by TAB1-mediated p38 alpha activation. Mol. Cell. Biol. 2004, 24, 6957-66.
11. Salvador, J. M.; Mittelstadt, P. R.; Guszczynski, T.; Copeland, T. D.; Yamaguchi, H.; Appella, E.; Fornace, A. J., Jr.; Ashwell, J. D. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat. Immunol. 2005, 6, 390-5.
12. Kotlyarov, A.; Neininger, A.; Schubert, C.; Eckert, R.; Birchmeier, C.; Volk, H. D.; Gaestel, M. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell. Biol. 1999, 1, 94-7.
13. Kotlyarov, A.; Yannoni, Y.; Fritz, S.; Laass, K.; Telliez, J. B.; Pitman, D.; Lin, L. L.; Gaestel, M. Distinct cellular functions of MK2. Mol. Cell. Biol. 2002, 22, 4827-35.
14. Naya, F. J.; Olson, E. MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. Curr. Opin. Cell Biol. 1999, 11, 683-8.
15. Saccani, S.; Pantano, S.; Natoli, G. p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat. Immunol. 2002, 3, 69-75.
16. Soloaga, A.; Thomson, S.; Wiggin, G. R.; Rampersaud, N.; Dyson, M. H.; Hazzalin, C. A.; Mahadevan, L. C.; Arthur, J. S. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003, 22, 2788-97.
17. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
18. Godl, K.; Wissing, J.; Kurtenbach, A.; Habenberger, P.; Blencke, S.; Gutbrod, H.; Salassidis, K.; Stein-Gerlach, M.; Missio, A.; Cotten, M.; Daub, H. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. Natl. Acad. Sci. USA 2003, 100, 15434-15439.
19. Fabian, M. A.; Biggs, W. H., 3rd; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23, 329-36.
20. Guo, X.; Gerl, R. E.; Schrader, J. W. Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase. J. Biol. Chem. 2003, 278, 22237-42.
21. Goebeler, M.; Kilian, K.; Gillitzer, R.; Kunz, M.; Yoshimura, T.; Brucker, E. B.; Rapp, U. R.; Ludwig, S. The MKK6/p38 stress kinase cascade is critical for tumor necrosis factor-alpha-induced expression of monocyte-chemoattractant protein-1 in endothelial cells. Blood 1999, 93, 857-65.
22. Dickfeld, T.; Lengyel, E.; May, A. E.; Massberg, S.; Brand, K.; Page, S.; Thielen, C.; Langenbrink, K.; Gawaz, M. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc. Res. 2001, 49, 189-99.
23. Takanami-Ohnishi, Y.; Amano, S.; Kimura, S.; Asada, S.; Utani, A.; Maruyama, M.; Osada, H.; Tsunoda, H.; Irukayama-Tomobe, Y.; Goto, K.; Karin, M.; Sudo, T.; Kasuya, Y. Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity. J. Biol. Chem. 2002, 277, 37896-903.
24. Wang, S. W.; Pawlowski, J.; Wathen, S. T.; Kinney, S. D.; Lichenstein, H. S.; Manthey, C. L. Cytokine mRNA decay is accelerated by an inhibitor of p38-mitogen-activated protein kinase. Inflamm. Res. 1999, 48, 533-8.
25. Vockerodt, M.; Pinkert, D.; Smola-Hess, S.; Michels, A.; Ransohoff, R. M.; Tesch, H.; Kube, D. The Epstein-Barr virus oncoprotein latent membrane protein 1 induces expression of the chemokine IP-10: importance of mRNA half-life regulation. Int. J. Cancer 2005, 114, 598-605.
26. Rovin, B. H.; Wilmer, W. A.; Danne, M.; Dickerson, J. A.; Dixon, C. L.; Lu, L. The in mitogen-activated protein kinase p38 is necesssary for interleukin 1beta-induced monocyte chemoattractant protein 1 expression by human mesangial cells. Cytokine 1999, 11, 118-26.
27. Hannigan, M. O.; Zhan, L.; Ai, Y.; Kotlyarov, A.; Gaestel, M.; Huang, C. K. Abnormal migration phenotype of mitogen-activated protein kinase-activated protein kinase 2-/- neutrophils in Zigmond chambers containing formyl-methionyl-leucyl-phenylalanine gradients. J. Immunol. 2001, 167, 3953-61.
28. Ayala, J. M.; Goyal, S.; Liverton, N. J.; Claremon, D. A.; O'Keefe, S. J.; Hanlon, W. A. Serum-induced monocyte differentiation and monocyte chemotaxis are regulated by the p38 MAP kinase signal transduction pathway. J. Leukoc. Biol. 2000, 67, 869-75.
29. Zhang, H.; Shi, X.; Hampong, M.; Blanis, L.; Pelech, S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J. Biol. Chem. 2001, 276, 6905-8.
30. Hefner, Y.; Borsch-Haubold, A. G.; Murakami, M.; Wilde, J. I.; Pasquet, S.; Schieltz, D.; Ghomashchi, F.; Yates, J. R., 3rd; Armstrong, C. G.; Paterson, A.; Cohen, P.; Fukunaga, R.; Hunter, T.; Kudo, I.; Watson, S. P.; Gelb, M. H. Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J. Biol. Chem. 2000, 275, 37542-51.
31. Finch, W. R. Mortality in rheumatoid disease. J. Insur. Med. 2004, 36, 200-12.
32. Palladino, M. A.; Bahjat, F. R.; Theodorakis, E. A.; Moldawer, L. L. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug. Discov. 2003, 2, 736-46.
33. Wei, S.; Kitaura, H.; Zhou, P.; Ross, F. P.; Teitelbaum, S. L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 2005, 115, 282-90.
34. Matsumoto, M.; Sudo, T., Saito, T.; Osada, H.; Tsujimoto, M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J. Biol. Chem. 2000, 275, 31155-61.
35. Hofbauer, L. C.; Schoppet, M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292, 490-5.
36. Ritchlin, C. T.; Haas-Smith, S. A.; Li, P.; Hicks, D. G.; Schwarz, E. M. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J. Clin. Invest. 2003, 111, 821-31.
37. Jolles, B. M,; Bogoch, E. R. Current consensus recommendations for rheumatoid arthrits therapy: a blind spot for osteoporosis prevention and treatment. J. Rheum. 2002, 29, 1814-1817.
38. Gough, A.; Lilley, J.; Eyre, S.; Holder, R.; Emery, P. Generalized bone loss in patients with early rheumatoid arthritis. Lancet 1994, 344, 23-27.
39. Gough, A.; Sambrook, P.; Devlin, J.; Huissoon, A.; Njeh, C.; Robbins, S.; Nguyen, T.; Emery, P. Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J. Rheum. 1998, 25, 1282-1289.
40. Bekker, P. J.; Holloway, D. L.; Rasmussen, A. S.; Murphy, R.; Martin, S. W.; Leese, P. T.; Holmes, G. B.; Dunstan, C. R.; DePaoli, A. M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women, J. Bone Miner. Res. 2004, 19, 1059-66.
41. Branger, J.; van den Blink, B.; WeiJer, S.; Madwed, J.; Bos, C. L.; Gupta, A.; Yong, C. L.; Polmar, S. H.; Olszyna, D. P.; Hack, C. E.; van Deventer, S. J.; Peppelenbosch, M. P.; van der Poll, T. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J. Immunol. 2002, 168, 4070-7.
42. Watkins, L. R.; Milligan, E. D.; Maier, S. F. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv. Exp. Med. Biol. 2003, 521, 1-21.
43. Ji, R. R.; Samad, T. A.; Jin, S. X.; Schmoll, R.; Woolf, C. J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002, 36, 57-68.
44. Schafers, M.; Svensson, C. I.; Sommer, C.; Sorkin, L. S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 2003, 23, 2517-21.
45. Jin, S. X.; Zhuang, Z. Y.; Woolf, C. J.; Ji, R. R. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J. Neurosci. 2003, 23, 4017-22.
46. Svensson, C. I.; Marsala, M.; Westerlund, A.; Calcutt, N. A.; Campana, W. M.; Freshwater, J. D.; Catalano, R.; Feng, Y.; Protter, A. A.; Scott, B.; Yaksh, T. L. Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J. Neurochem. 2003, 86, 1534-44.
47. Svensson, C. I.; Hua, X. Y.; Protter, A. A.; Powell, H. C.; Yaksh, T. L. Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia. Neuroreport 2003, 14, 1153-7.
48. Tong, S.; Daniels, S.; Montano, T.; Chang, S.; Desjardins, P. SCIO-469, a novel P38α MAPK Inhibitor, provides efficacy in acute post-surgical dental pain. Clin. Pharmacol. Ther. 2004, 75, P3.
49. Nick, J. A.; Young, S. K.; Brown, K. K.; Avdi, N. J.; Arndt, P. G., Suratt, B. T.; Janes, M. S.; Henson, P. M.; Worthen, G. S. Role of p38 mitogen-activated protein kinase in a routine model of pulmonary inflammation. J. Immunol. 2000, 164, 2151-9.
50. Nick, J. A.; Young, S. K.; Arndt, P. G.; Lieber, J. G.; Suratt, B. T.; Poch, K. R,; Avdi, N. J.; Malcolm, K. C.; Taube, C.; Henson, P. M.; Worthen, G. S. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J. Immunol. 2002, 169, 5260-9.
51. Haddad, E. B.; Birrell, M.; McCluskie, K.; Ling, A.; Webber, S. E.; Foster, M. L.; Belvisi, M. G. Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br. J. Pharmacol. 2001, 132, 1715-24.
52. Underwood, D. C.; Osborn, R. R.; Bochnowicz, S.; Webb, E. F.; Rieman, D. J.; Lee, J. C.; Romanic, A. M.; Adams, J. L.; Hay, D. W.; Griswold, D. E. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L895-902.
53. Platanias, L. C. Map kinase signaling pathways and hematologic malignancies. Blood 2003, 101, 4667-79.
54. Hideshima, T.; Akiyama, M.; Hayashi, T.; Richardson, P.; Schlossman, R.; Chauhan, D.; Anderson, K. C. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003, 101, 703-5.
55. Giuliani, N.; Colin, S.; Rizzoli, V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp. Hematol. 2004, 32, 685-91.
56. Li, X.; Udagawa, N.; Itoh, K.; Suda, K.; Murase, Y.; Nishihara, T.; Suda, T.; Takahashi, N. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002, 143, 3105-13.
57. Matsuyama, W.; Wang, L.; Farrar, W. L.; Faure, M.; Yoshimura, T. Activation of discoidin domain receptor 1 isoform b with collagen up-regulates chemokine production in human macrophages: role of p38 mitogen-activated protein kinase and NF-kappa B. J. Immunol. 2004, 172, 2332-40.
58. Hideshima, T.; Podar, K.; Chauhan, D.; Ishitsuka, K.; Mitsiades, C.; Tai, Y. T.; Hamasaki, M.; Raje, N.; Hideshima, H.; Schreiner, G.; Nguyen, A. N.; Navas, T.; Munshi, N. C.; Richardson, P. G.; Higgins, L. S.; Anderson, K. C. p38 MAPK inhibition enhances PS-341 (bortezomibb)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004, 23, 8766-76.
59. Nissen, S. E.; Tuzcu, E. M.; Schoenhagen, P.; Crowe, T.; Sasiela, W. J.; Tsai, J.; Orazem, J.; Magorien, R. D.; O'Shaughnessy, C.; Ganz, P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 2005, 352, 29-38.
60. Ridker, P. M.; Cannon, C. P.; Morrow, D,; Rifai, N.; Rose, L. M.; McCabe, C. H.; Pfeffer, M. A.; Braunwald, E. C-reactive protein levels and outcomes after statin therapy, N. Engl. J. Med. 2005, 352, 20-8.
61. Zhao, M.; Liu, Y,; Wang, X.; New, L.; Han, J.; Brunk, U. T. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL. APMIS 2002, 110, 458-68.
62. Wang, Z.; Castresana, M. R.; Newman, W. H. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. J. Mol. Cell. Cardiol. 2004, 36, 49-56.
63. Buerkle, M. A.; Lehrer, S.; Sohn, H. Y.; Conzen, P.; Pohl, U.; Krotz, F. Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo. Circulation 2004, 110, 2053-9.
64. Branger, J.; van den Blink, B.; WeiJer, S.; Gupta, A.; van Deventer, S. J.; Hack, C. E.; Peppelenbosch, M. P.; van der Poll, T. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood 2003, 101, 4446-8.